Intracavitary Therapeutics for Pleural Malignancies

Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavit...

Full description

Saved in:
Bibliographic Details
Published inClinics in chest medicine Vol. 39; no. 1; p. 195
Main Authors Murthy, Vivek, Mangalick, Keshav, Sterman, Daniel H
Format Journal Article
LanguageEnglish
Published United States 01.03.2018
Subjects
Combined Modality Therapy - methods
Female
Humans
Male
Mesothelioma - pathology
Mesothelioma - therapy
Pleural Neoplasms - pathology
Pleural Neoplasms - therapy
Pleural malignancies
Pleural space
Mesothelioma
Intracavity therapeutics
Online AccessGet more information

Cover

More Information
Summary:Pleural malignancies remain a serious therapeutic challenge, and are frequently refractory to standard treatment; however, they have the advantage of occurring in an enclosed cavity readily accessible for examination, biopsy, and serial sampling. Novel therapeutics can be administered via intracavitary delivery to maximize efficacy by targeting the site of involvement and potentially mitigating the adverse effects of systemic therapies. The easy accessibility of the pleural space lends itself well to repeated sampling and analysis to determine efficacy and toxicity of a given treatment paradigm. These factors support the rationale for delivery of novel therapeutics directly into the pleural space.
ISSN:1557-8216
DOI:10.1016/j.ccm.2017.11.003